Role Of The C-C Motif Chemokine Ligand 5 (CCL5) And Its Receptor, C-C Motif Chemokine Receptor 5 (CCR5) In The Genesis Of Aldosterone-induced Hypertension, Vascular Dysfunction, And End-organ Damage
Preprint
Abstract
Background: Aldosterone, a mineralocorticoid steroid hormone, has been described to initiate cardiovascular diseases by triggering exacerbated sterile vascular inflammation. The functions of C-C Motif Chemokine Ligand 5 (CCL5) and its receptor, C-C Motif Chemokine Receptor 5 (CCR5), are well known in infectious diseases, but their roles in the genesis of aldosterone-induced vascular injury and hypertension are unknown. Methods: We analyzed the vascular profile, blood pressure, and renal damage in wild-type (CCR5 +/+ ) and CCR5 knockout (CCR5 −/− ) mice treated with aldosterone (600 µg/kg/day for 14 days) while receiving 1% saline to drink. Results: Here, we show that CCR5 plays a central role in aldosterone-induced vascular injury, hypertension, and renal damage. Long-term infusion of aldosterone in CCR5 +/+ mice resulted in exaggerated CCL5 circulating levels and vascular CCR5 expression. Aldosterone treatment also triggered vascular injury, characterized by endothelial dysfunction and inflammation, hypertension, and renal damage. Mice lacking CCR5 were protected from aldosterone-induced vascular damage, hypertension, and renal injury. Mechanistically, we demonstrated that CCL5 increased NADPH oxidase 1 (Nox1) expression, reactive oxygen species (ROS) formation, NFκB activation, and inflammation and reduced nitric oxide production in isolated endothelial cells. These effects were abolished by antagonizing CCR5 with Maraviroc. Finally, aortae incubated with CCL5 displayed severe endothelial dysfunction, which is prevented by blocking Nox1, NFκB, or with Maraviroc treatment. Conclusions: Our data demonstrate that CCL5/CCR5, through activation of NFkB and Nox1, is critically involved in aldosterone-induced vascular and renal damage and hypertension. Our data place CCL5 and CCR5 as potential targets for therapeutic interventions in conditions with aldosterone excess.Keywords
This publication has 65 references indexed in Scilit:
- Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in MiceCirculation, 2013
- Cardiomyocyte Mineralocorticoid Receptors Are Essential for Deoxycorticosterone/Salt-Mediated Inflammation and Cardiac FibrosisHypertension, 2012
- Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptorsNature Medicine, 2012
- Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseasesFree Radical Biology and Medicine, 2012
- T Regulatory Lymphocytes Prevent Aldosterone-Induced Vascular InjuryHypertension, 2012
- Chemokine receptor CCR5: from AIDS to atherosclerosisBritish Journal of Pharmacology, 2011
- Aldosterone and Vascular InflammationHypertension, 2008
- Role of the T cell in the genesis of angiotensin II–induced hypertension and vascular dysfunctionJournal of Experimental Medicine, 2007
- Role of the Renin-Angiotensin-Aldosterone System and Proinflammatory Mediators in Cardiovascular DiseaseThe American Journal of Cardiology, 2006
- Aldosterone Activates Vascular p38MAP Kinase and NADPH Oxidase Via c-SrcHypertension, 2005